Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Arcoma AB's Enterprise Value is kr98.6 Mil.
Arcoma AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was kr4.9 Mil. Therefore, Arcoma AB's EV-to-EBIT ratio for today is 20.30.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Arcoma AB's Enterprise Value is kr98.6 Mil.
Arcoma AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was kr11.9 Mil. Therefore, Arcoma AB's EV-to-EBITDA ratio for today is 8.31.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Arcoma AB's Enterprise Value is kr98.6 Mil.
Arcoma AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was kr127.1 Mil. Therefore, Arcoma AB's EV-to-Revenue ratio for today is 0.78.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Arcoma AB's Enterprise Value is kr98.6 Mil.
Arcoma AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was kr15.6 Mil. Therefore, Arcoma AB's EV-to-FCF ratio for today is 6.31.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Arcoma AB (OSTO:ARCOMA) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Arcoma AB's current Enterprise Value is kr98.6 Mil.
Arcoma AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr4.9 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Arcoma AB's current Enterprise Value is kr98.6 Mil.
Arcoma AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr11.9 Mil.
Arcoma AB's current Enterprise Value is kr98.6 Mil.
Arcoma AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr127.1 Mil.
Arcoma AB's current Enterprise Value is kr98.6 Mil.
Arcoma AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr20.5 Mil.
Arcoma AB's current Enterprise Value is kr98.6 Mil.
Arcoma AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr15.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcoma AB Enterprise Value Related Terms
Arcoma AB Enterprise Value Historical Data
* Premium members only.
The historical data trend for Arcoma AB's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ARCOMA vs ABT, SYK, MDT: Enterprise Value Comparison
For the Medical Devices subindustry, Arcoma AB's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcoma AB Enterprise Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Arcoma AB's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Arcoma AB's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Arcoma AB's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcoma AB (OSTO:ARCOMA) has a Enterprise Value of kr98.6 Mil as of Jul. 02, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Arcoma AB and its competitors.
Is Arcoma AB's Enterprise Value too high?
Arcoma AB's current Enterprise Value is kr98.6 Mil. Overall, Arcoma AB has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Arcoma AB's Enterprise Value compare to ABT and SYK?
Arcoma AB's Enterprise Value of kr98.6 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Arcoma AB and its competitors. Arcoma AB's current Enterprise Value is kr98.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcoma AB stock overvalued right now?
Based on GuruFocus' analysis, Arcoma AB (OSTO:ARCOMA) is currently considered Fairly Valued. The stock's GF Value™ is kr7.86, compared to a current price of kr8.56 — trading 8.9% above its estimated fair value. The current Enterprise Value is kr98.6 Mil. Arcoma AB's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Arcoma AB (OSTO:ARCOMA), the current Enterprise Value is kr98.6 Mil as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcoma AB (OSTO:ARCOMA) Overvalued in 2026?
Based on GuruFocus' analysis, Arcoma AB stock appears to be overvalued.
The current stock price of kr8.56 is trading 8.9% above its estimated GF Value™ of kr7.86.
GuruFocus considers Arcoma AB to be Fairly Valued.
Key valuation signals for OSTO:ARCOMA:
Enterprise Value: kr98.6 Mil
GF Value™: kr7.86 vs. price of kr8.56 (8.9% above fair value)
No single metric tells the full story. See the OSTO:ARCOMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcoma AB provides digital radiography systems in Sweden. It offers products including wireless flat panel detectors, positioning devices, and precision dr systems.
75GF Score
Get the complete analysis for OSTO:ARCOMA
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ARCOMA has been successfully added to your 
